Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell–cell fusion, and neutralization sensitivity

References

• Garcia-Beltran WF, Lam EC, St. Denis K, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184:2523. doi:10.1016/j.cell.2021.04.006.
   PubMed Web of Science ®Google Scholar
• Singh J, Rahman SA, Ehtesham NZ, et al. SARS-CoV-2 variants of concern are emerging in India. Nat Med. 2021. doi:10.1038/s41591-021-01397-4.
   Web of Science ®Google Scholar
• Outbreak.info.  Available from: https://outbreak.info/.
   Google Scholar
• Deng X, et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell. 2021. doi:10.1016/j.cell.2021.04.025.
   Web of Science ®Google Scholar
• Li Q, Wu J, Nie J, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020;182:1284–1294.e9. doi:10.1016/j.cell.2020.07.012.
   PubMed Web of Science ®Google Scholar
• Wise J. Covid-19: the E484K mutation and the risks it poses. Br Med J. 2021;372:n359. doi:10.1136/bmj.n359.
   PubMed Web of Science ®Google Scholar
• Wang P, Casner RG, Nair MS, et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe. 2021;29:747–751.e4. doi:10.1016/j.chom.2021.04.007.
   PubMed Web of Science ®Google Scholar
• Li Q, Nie J, Wu J, et al. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell. 2021;184:2362–2371.e9. doi:10.1016/j.cell.2021.02.042.
   PubMed Web of Science ®Google Scholar
• Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593:130–135. doi:10.1038/s41586-021-03398-2.
   PubMed Web of Science ®Google Scholar
• Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med. 2021;27:917–924. doi:10.1038/s41591-021-01318-5.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Arora P, Groß R, et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021;184:2384–2393.e12. doi:10.1016/j.cell.2021.03.036.
   PubMed Web of Science ®Google Scholar
• Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182:812–827.e19. doi:10.1016/j.cell.2020.06.043.
   PubMed Web of Science ®Google Scholar
• Weissman D, Alameh M-G, de Silva T, et al. D614g spike mutation increases SARS CoV-2 susceptibility to neutralization. Cell Host Microbe. 2021;29:23–31.e4. doi:10.1016/j.chom.2020.11.012.
   PubMed Web of Science ®Google Scholar
• Plante JA, Liu Y, Liu J, et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2021;592:116–121. doi:10.1038/s41586-020-2895-3.
   PubMed Web of Science ®Google Scholar
• Johnson BA, Xie X, Bailey AL, et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature. 2021;591:293–299. doi:10.1038/s41586-021-03237-4.
   PubMed Web of Science ®Google Scholar
• Lubinski B, Tang T, Daniel S, et al. Functional evaluation of proteolytic activation for the SARS-CoV-2 variant B.1.1.7: role of the P681H mutation. bioRxiv: the preprint server for biology, 2021. doi:10.1101/2021.04.06.438731.
   Google Scholar
• Zhang L, et al. Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation. bioRxiv, 2021. doi:10.1101/2021.02.05.429982.
   Google Scholar
• Nie J, Li Q, Wu J, et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat Protoc. 2020;15:3699–3715. doi:10.1038/s41596-020-0394-5.
   PubMed Web of Science ®Google Scholar
• Zhang L, Li Q, Nie J, et al. Cellular tropism and antigenicity of mink-derived SARS-CoV-2 variants. Signal Transduct Target Ther. 2021;6:196. doi:10.1038/s41392-021-00617-0.
   PubMed Web of Science ®Google Scholar
• Kondo N, Miyauchi K, Meng F, et al. Conformational changes of the HIV-1 envelope protein during membrane fusion are inhibited by the replacement of its membrane-spanning domain. J Biol Chem. 2010;285:14681–14688. doi:10.1074/jbc.M109.067090.
   PubMed Web of Science ®Google Scholar
• Shi R, Shan C, Duan X, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020; 584:120–124. doi:10.1038/s41586-020-2381-y.
   PubMed Web of Science ®Google Scholar
• Pan HX, et al. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. Chin Med J. 2021. doi:10.1097/cm9.0000000000001573.
   Google Scholar
• Wu S, Zhong G, Zhang J, et al. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nature communications. 2020;11:4081. doi:10.1038/s41467-020-17972-1
   Web of Science ®Google Scholar
• WHO. COVID-19 weekly epidemiological update. 2021 May 9. https://covid19.who.int.
   Google Scholar
• Shuai H, et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 omicron. Nature. 2022. doi:10.1038/s41586-022-04442-5.
   Web of Science ®Google Scholar
• Ranjan R, Sharma A, Verma MK. Characterization of the Second Wave of COVID-19 in India; 2021. 2021.2004.2017.21255665, %J medRxiv. doi:10.1101/2021.04.17.21255665.
   Google Scholar
• Starr TN, Greaney AJ, Hilton SK, et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell. 2020;182:1295–1310.e20. doi:10.1016/j.cell.2020.08.012.
   PubMed Web of Science ®Google Scholar
• Cherian S, et al. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India; 2021. 2021.2004.2022.440932, %J bioRxiv. doi:10.1101/2021.04.22.440932.
   Google Scholar
• Huang K, Zhang Y, Hui X, et al. Q493k and Q498H substitutions in spike promote adaptation of SARS-CoV-2 in mice. EBioMedicine. 2021;67:103381. doi:10.1016/j.ebiom.2021.103381.
   PubMed Web of Science ®Google Scholar
• Gu H, Chen Q, Yang G, et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science. 2020;369:1603–1607. doi:10.1126/science.abc4730.
   PubMed Web of Science ®Google Scholar
• Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci USA. 2020;117:11727–11734. doi:10.1073/pnas.2003138117.
   PubMed Web of Science ®Google Scholar
• Walls AC, Park Y-J, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281–292.e6. doi:10.1016/j.cell.2020.02.058.
   PubMed Web of Science ®Google Scholar
• Bestle D, Heindl MR, Limburg H, et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance. 2020;3. doi:10.26508/lsa.202000786.
   PubMed Web of Science ®Google Scholar
• Xia S, Liu M, Wang C, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020;30:343–355. doi:10.1038/s41422-020-0305-x.
   PubMed Web of Science ®Google Scholar
• Saito A, Irie T, Suzuki R, et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature. 2022;602:300–306. doi:10.1038/s41586-021-04266-9.
   PubMed Web of Science ®Google Scholar
• Zhang J, Xiao T, Cai Y, et al. Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant. Science. 2021;374:1353–1360. doi:10.1126/science.abl9463.
   PubMed Web of Science ®Google Scholar
• Liu Z, VanBlargan LA, Bloyet L-M, et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. 2021;29:477–488.e4. doi:10.1016/j.chom.2021.01.014.
   PubMed Web of Science ®Google Scholar
• Truong TT, et al. Persistent SARS-CoV-2 infection and increasing viral variants in children and young adults with impaired humoral immunity. medRxiv, 2021. doi:10.1101/2021.02.27.21252099.
   Google Scholar
• Tchesnokova V, Kulasekara H, Larson L, et al. Acquisition of the L452R mutation in the ACE2-binding interface of spike protein triggers recent massive expansion of SARS-CoV-2 variants. J Clin Microbiol. 2021;59:e0092121. doi:10.1128/JCM.00921-21.
   PubMed Web of Science ®Google Scholar
• Kumar VJ, Banu S, Sasikala M, et al. Effectiveness of REGEN-COV antibody cocktail against the B.1.617.2 (delta) variant of SARS-CoV-2: A cohort study. J Intern Med. 2022;291:80–383. doi:10.1111/joim.13408.
   Web of Science ®Google Scholar
• Edara V-V, et al. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. 2021.2005.2009.443299, %J bioRxiv. 2021. doi:10.1101/2021.05.09.443299.
   Google Scholar
• Yadav PD, et al. Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. Clinical Infect Dis. 2021. doi:10.1093/cid/ciab411.
   Web of Science ®Google Scholar
• McCallum M, De Marco A, Lempp FA, et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell. 2021;184:2332–2347.e16. doi:10.1016/j.cell.2021.03.028.
   PubMed Web of Science ®Google Scholar
• Wang S, Qiu Z, Hou Y, et al. AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. Cell research. 2021;31:126–140. doi:10.1038/s41422-020-00460-y.
   PubMed Web of Science ®Google Scholar
• Long B, Carius BM, Chavez S, et al. Clinical update on COVID-19 for the emergency clinician: presentation and evaluation. Am J Emerg Med. 2022;54:46–57. doi:10.1016/j.ajem.2022.01.028.
   PubMed Web of Science ®Google Scholar
• Khoury DS, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021. doi:10.1038/s41591-021-01377-8.
   PubMed Web of Science ®Google Scholar